Against the clock towards new Ebola virus therapies.

[1]  M. Altfeld,et al.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. , 2016, The New England journal of medicine.

[2]  W. L. Shupert,et al.  An Ebola whole-virus vaccine is protective in nonhuman primates , 2015, Science.

[3]  Elizabeth L. Beam,et al.  The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Alexander Gutfraind,et al.  Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia. , 2015, The Journal of infectious diseases.

[5]  M. Levine,et al.  How the current West African Ebola virus disease epidemic is altering views on the need for vaccines and is galvanizing a global effort to field-test leading candidate vaccines. , 2015, The Journal of infectious diseases.

[6]  Edward Wright,et al.  A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. , 2015, The New England journal of medicine.

[7]  A. Lefor,et al.  Favipiravir: A New Medication for the Ebola Virus Disease Pandemic , 2014, Disaster Medicine and Public Health Preparedness.

[8]  Christopher Dye,et al.  Ebola vaccine--an urgent international priority. , 2014, The New England journal of medicine.

[9]  Rachel S. G. Sealfon,et al.  Clinical illness and outcomes in patients with Ebola in Sierra Leone. , 2014, The New England journal of medicine.

[10]  Stephan Günther,et al.  Emergence of Zaire Ebola virus disease in Guinea. , 2014, The New England journal of medicine.

[11]  Jon Cohen.  Infectious disease. Ebola vaccine: little and late. , 2014, Science.

[12]  Rachel S. G. Sealfon,et al.  Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak , 2014, Science.

[13]  D. Florescu,et al.  Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses , 2014, Expert review of anti-infective therapy.

[14]  Mario Roederer,et al.  Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge , 2014, Nature Medicine.

[15]  J. Strong,et al.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™ , 2014, Nature.

[16]  S. Günther,et al.  Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. , 2014, Antiviral research.

[17]  M. Manns,et al.  The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry , 2014, The Journal of antimicrobial chemotherapy.

[18]  H. Feldmann,et al.  Ebola virus vaccines: an overview of current approaches , 2014, Expert review of vaccines.

[19]  Gianluca Pegoraro,et al.  Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 , 2014, Nature.

[20]  Paul Shinn,et al.  Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs , 2014, Emerging Microbes & Infections.

[21]  B. Gowen,et al.  Favipiravir (T-705) Inhibits Junín Virus Infection and Reduces Mortality in a Guinea Pig Model of Argentine Hemorrhagic Fever , 2013, PLoS neglected tropical diseases.

[22]  X. Qiu,et al.  Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb , 2013, Scientific Reports.

[23]  X. Qiu,et al.  mAbs and Ad-Vectored IFN-α Therapy Rescue Ebola-Infected Nonhuman Primates When Administered After the Detection of Viremia and Symptoms , 2013, Science Translational Medicine.

[24]  H. Feldmann,et al.  Antiviral Efficacy of Favipiravir against Two Prominent Etiological Agents of Hantavirus Pulmonary Syndrome , 2013, Antimicrobial Agents and Chemotherapy.

[25]  J. Choi,et al.  Emerging Targets and Novel Approaches to Ebola Virus Prophylaxis and Treatment , 2013, BioDrugs.

[26]  Kathryn L. Schornberg,et al.  FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection , 2013, Science Translational Medicine.

[27]  H. Feldmann,et al.  Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine , 2013, PLoS pathogens.

[28]  P. Jahrling,et al.  Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. , 2012, Vaccine.

[29]  Peter B. Jahrling,et al.  Clinical Management of Filovirus-Infected Patients , 2012, Viruses.

[30]  J. Neyts,et al.  Favipiravir (T-705) inhibits in vitro norovirus replication. , 2012, Biochemical and biophysical research communications.

[31]  H. Feldmann,et al.  Current ebola vaccines , 2012, Expert opinion on biological therapy.

[32]  B. G. Davis,et al.  Virus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infection , 2012, Nature Communications.

[33]  R. Kurth,et al.  Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene. , 2011, Journal of virological methods.

[34]  A. MacNeil,et al.  Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda , 2010, Emerging infectious diseases.

[35]  Jens H. Kuhn,et al.  Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations , 2010, Archives of Virology.

[36]  G. Kobinger,et al.  Recent advances in Ebolavirus vaccine development , 2010, Human vaccines.

[37]  G. Neumann,et al.  Minigenome-Based Reporter System Suitable for High-Throughput Screening of Compounds Able To Inhibit Ebolavirus Replication and/or Transcription , 2010, Antimicrobial Agents and Chemotherapy.

[38]  A. García-Sastre,et al.  An enzymatic virus-like particle assay for sensitive detection of virus entry. , 2010, Journal of virological methods.

[39]  X. Qiu,et al.  Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses , 2009, PloS one.

[40]  D. Smee,et al.  T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections , 2009, Antiviral Research.

[41]  C. Staib,et al.  Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection. , 2009, Journal of virological methods.

[42]  Paolo Ascenzi,et al.  Ebolavirus and Marburgvirus: insight the Filoviridae family. , 2008, Molecular aspects of medicine.

[43]  W. Kalina,et al.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. , 2007, The Journal of infectious diseases.

[44]  J. Aronson.  Old drugs--new uses. , 2007, British journal of clinical pharmacology.

[45]  S. Soignet,et al.  Diagnosis and treatment of acute promyelocytic leukemia , 2007, Current oncology reports.

[46]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[47]  Gian Franco Gensini,et al.  The contributions of Paul Ehrlich to infectious disease. , 2007, Journal of Infection.

[48]  D. Burton,et al.  Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys , 2007, PLoS pathogens.

[49]  Carola Engler,et al.  Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors , 2006, Proceedings of the National Academy of Sciences.

[50]  P. Jahrling,et al.  Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference , 2006, The Journal of infectious diseases.

[51]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[52]  M. Aman,et al.  Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. , 2005, Vaccine.

[53]  H. Feldmann,et al.  RNA Polymerase I-Driven Minigenome System for Ebola Viruses , 2005, Journal of Virology.

[54]  David W Carley,et al.  Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I. , 2005, IDrugs : the investigational drugs journal.

[55]  David W Carley,et al.  Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part II. , 2005, IDrugs : the investigational drugs journal.

[56]  Tokiko Watanabe,et al.  Production of Novel Ebola Virus-Like Particles from cDNAs: an Alternative to Ebola Virus Generation by Reverse Genetics , 2004, Journal of Virology.

[57]  M. Hamburg.  Public Health Preparedness , 2002, Science.

[58]  P. Jahrling,et al.  Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. , 1999, The Journal of infectious diseases.

[59]  A. Chepurnov,et al.  Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. , 1999, The Journal of infectious diseases.

[60]  R. Colebunders,et al.  Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. , 1999, The Journal of infectious diseases.

[61]  I. Borisevich,et al.  [Development and study of the properties of immunoglobulin against Ebola fever]. , 1995, Voprosy virusologii.

[62]  J. Huggins.  Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. , 1989, Reviews of infectious diseases.

[63]  P. Piot,et al.  ISOLATION OF MARBURG-LIKE VIRUS FROM A CASE OF HÆMORRHAGIC FEVER IN ZAIRE , 1977, The Lancet.

[64]  N. Fiotti,et al.  Improving siRNA bio-distribution and minimizing side effects. , 2011, Current drug metabolism.

[65]  P. Casamassimo,et al.  Old drugs, new uses. , 2011, Pediatric dentistry.

[66]  J. McCormick,et al.  Experimental filovirus infections. , 1999, Current topics in microbiology and immunology.

[67]  P. Jahrling,et al.  Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. , 1996, Archives of virology. Supplementum.

[68]  Ebola haemorrhagic fever in Zaire, 1976. , 1978, Bulletin of the World Health Organization.